N/A N=70 Hysterectomy by Transabdominal Laparoscopy or NOTES
Uterine Diseases
Primary: Successful Removal of the Uterus Without Conversion to Another Technique — 35; 35 Participants — p=0.0221
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=49 Vaginally Assisted Laparoscopic Hysteropexy Versus Vaginal Hysterectomy
Pelvic Organ Prolapse
Primary: Number of Participants With Recurrence of Pelvic Organ Prolapse — 0; 0 Participants
N/A N=700 Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer
Cervical Cancer
Primary: Pelvic Recurrence Rate at 3 Years — 2.17; 2.52 percentage of participants
Phase 2 N=11 Pilot Study of MRI-Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids
Uterine Fibroids · Uterine Leiomyomata
Primary: Treatment-related Adverse Events (AE) Per Subject Resulting From HIFU Treatment of the Uterine Fibroids — 1.3 treatment-related AE/patient
Phase 3 N=236 Hysterectomy and Levonorgestrel Releasing Intrauterine System (LNG-IUS) in the Treatment of Menorrhagia
Menorrhagia
Primary: HRQoL (Health Related Quality of Life) — 0.08; 0.10 points on a scale
N/A N=15 Radiofrequency Ablation of Adenomyosis
Adenomyosis
Primary: Post-operative Evidence of Adenomyoma Tissue Ablation Effect by Area (n) as Assessed by Pathological Analysis — 9; 8; 7; 6 treated areas
N/A N=9 Magnetic Resonance (MR) Guided Focused Ultrasound Surgery of Uterine Fibroids
Leiomyoma
Primary: Number and Type of Adverse Events — 15 Adverse Events
N/A N=73 Clinical Study of the Mirabilis High-Intensity Focused Ultrasound System for Non-Invasive Treatment of Uterine Fibroids
Uterine Fibroids (Leiomyomas)
Primary: Evaluation of All Adverse Events Encountered — 0; 0.95 Adverse Device Effects / patient
N/A N=33 Therapeutic Magnetic Resonance Imaging (MRI)-Guided High Intensity Focused Ultrasound (HIFU) Ablation of Uterine Fibroids
Uterine Fibroids
Primary: Adverse Events/Subject Resulting From HIFU Treatment of the Uterine Fibroids — 2.6 Adverse Event/subject
N/A N=84 Urinary Retention After Total Laparoscopic Hysterectomy With Immediate Foley Catheter Removal Versus Backfill Void Trial
Urinary Retention · Voiding Disorders
Primary: Number of Participants With Void Trial Failure Rate — 7; 11 Participants
N/A N=3 Hysteroscopic Cryomyolysis for the Treatment of Submucosal Leiomyomata
Uterine Fibroids · Leiomyoma · Menorrhagia
Primary: Number of Adverse Events — 1 Participants
N/A N=3 Safety and Effectiveness of OCL 503 in the Treatment of Women With Leiomyomata
Leiomyomata
Primary: Number of Participants With Serious Adverse Events — 0; 0 Participants
N/A N=50 Robot Assisted Laparoscopic Hysterectomy vs. Abdominal Hysterectomy in Endometrial Cancer
Endometrial Cancer
Primary: Health Related Quality of Life (HRQoL) — 0.34; 0.30; 0.66; 0.48 scores on a scale — p=0.011
N/A N=137 Laparoscopic Radiofrequency Ablation (RFA) of Symptomatic Uterine Fibroids
Uterine Fibroids · Uterine Myomas
Primary: Assessment of Menstrual Blood Flow (MBF) at 12 Months Post Procedure — 40.2; 48.8; 59.1; 67.7 Percentage of participants
N/A N=97 Laparoscopic Enclosed Morcellation; Electromechanic Morcellation vs Vaginal Removal
Myoma
Primary: Operation Time — 146.1; 124.6 seconds
Phase 3 N=68 Multimodal Pain Management After Robotic-Assisted Total Laparoscopic Hysterectomy
Pain, Postoperative
Primary: Total Opioid Pain Medications Required 0-3h Post op in Morphine Milligram Equivalents (MME) — 2.00; 5.32 morphine milligram equivalents (MME)
Phase 4 N=106 Evaluation of Modified Treatment Regimens for Treatment of Heavy Menstrual Bleeding Using the HerOption® System
Menorrhagia
Primary: Success (Reduction in Menstruation to Normal Levels) — 59 Participants — p=.271
N/A N=60 Histerectomy Vs Partial Myometrial Resection for Placenta Accreta Spectrum
Placenta Accreta
Primary: Feasibility: Proportion of Eligible Patients Who Agree to Participate in the Study. — 60 Participants
Phase 4 N=40 Harmonic ACE®+7 Shears in Laparoscopic Hysterectomy
Benign Disease Where Total Hysterectomy is Indicated
Primary: Percentage of Subjects Achieving Hemostasis at the Named Vessel/Pedicle (UA or UP) on the Left Side. — 97.5 percentage of participants
N/A N=74 HOME Study: Hysteroscopic Office Myomectomy Evaluation
Uterine Fibroids · Polyps
Primary: Percent Reduction in Target Pathology Volume — 96.9; 99.9 percentage of fibriods/polyps
N/A N=104 Quality of Life in Premenopausal Women With Heavy Menstrual Bleeding
Heavy Menstrual Bleeding
Primary: Hot Flush Frequency Total Score (HFRS) Change — 9.3; 8.8; 12.7 score on a scale
N/A N=183 Study of Uterine Prolapse Procedures - Randomized Trial
Uterovaginal Prolapse
Primary: Cumulative Failure — 78; 69; 9; 16 Participants
Early Phase 1 N=103 Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study
Cervical Cancer · Uterine Endometrial Cancer · Ovarian Cancer
Primary: Hospital Stay — 3.0; 3.0 Days — p=0.36
N/A N=35 Ultravision Visual Clearing System in Laparoscopic Hysterectomy and Myomectomy
Pain · Hysterectomy · Myomectomy
Primary: Quality of Surgical Field Visualization — 9; 1; 5; 2 participants
N/A N=52 Disposable Energy Sources and Operating Room Time for Laparoscopic Hysterectomy
Benign Uterine Disease
Primary: The Primary Endpoint of This Study is Time Difference Between Cauterizing One Side of the Uterine Attachments, From the Round Ligament to the Uterine Artery on One Side…
N/A N=290 MyoSure Hysteroscopic Tissue Removal System Registry Study
Uterine Fibroids · Polyps
Primary: Procedure Efficacy — 95.4 percent of pathology
Phase 4 N=67 Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia
Menorrhagia
Primary: Menstrual Blood Loss (MBL) as Measured by Pictorial Blood Loss Assessment Chart (PBLAC). — 15; 0 units on a scale — p=0.003
N/A N=236 Apical Support During Hysterectomy for Pelvic Organ Prolapse
Pelvic Organ Prolapse
Primary: Proportion of Patients Having Concurrent Apical Suspension Performed — 66 Participants
N/A N=11 Clinical Evaluation of the Interlace Medical Hysteroscopic Morcellator
Abnormal Uterine Bleeding · Infertility
Primary: Percentage of Tissue Removed — 97.5 Percentage of tissue removed
Phase 3 N=301 PGL4001 Versus GnRH-agonist in Uterine Myomas
Uterine Myomas
Primary: Percentage of Subjects With Reduction of Uterine Bleeding at Week 13 Visit Defined as Pictorial Blood-loss Assessment Chart (PBAC) Score < 75 at End-of-treatment Visit…